Leveraging Molecular Data Analysis to Understand Drug Response in Systemic Sclerosis

Abstract

Taroni et al. integrate and analyze genomic information generated from different clinical trials on systemic sclerosis, a disease for which there is yet no Food and Drug Administration-approved therapy. By using a recent network analysis approach based on tissue-specific functionality, they leverage the biological information extracted from molecular profiling studies and report findings that could be useful for patient stratification.